- Home
- SITC vs ANTX Comparison
SITC vs ANTX Comparison
Compare SITC & ANTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SITC | ANTX |
|---|---|---|
| Founded | 1965 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 154.8M | 172.9M |
| IPO Year | 1994 | 2022 |
Fundamental Metrics
Financial Performance| Metric | SITC | ANTX |
|---|---|---|
| Price | $3.77 | $3.58 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $9.00 |
| AVG Volume (30 Days) | ★ 2.0M | 304.7K |
| Earning Date | 11-02-2026 | 11-11-2026 |
| Dividend Yield | ★ 107.82% | N/A |
| EPS Growth | N/A | ★ 32.56 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $123,649,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.80 | $1.00 |
| 52 Week High | $8.91 | $7.19 |
Technical Indicators
Market Signals| Indicator | SITC | ANTX |
|---|---|---|
| Relative Strength Index (RSI) | 72.80 | 29.86 |
| Support Level | $2.89 | $2.87 |
| Resistance Level | $4.55 | $5.15 |
| Average True Range (ATR) | 0.14 | 0.35 |
| MACD | 0.07 | -0.08 |
| Stochastic Oscillator | 90.86 | 14.65 |
Price Performance
Historical ComparisonAbout SITC SITE Centers Corp.
SITE Centers Corp is a self-administered and self-managed REIT that operates as a fully integrated real estate company. The company is engaged in the business of owning, leasing, acquiring, redeveloping, developing, and managing shopping centers.
About ANTX AN2 Therapeutics Inc.
AN2 Therapeutics Inc is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform. The company has a pipeline of boron-based compounds in development for Chagas disease, non-tuberculous mycobacterial (NTM) and melioidosis, along with early-stage programs focused on targets in infectious diseases and oncology. Product candidate AN2-502998 Epetraborole.